Research Information Only — Educational content, not medical advice. BPC-157 and TB-500 are research compounds, not FDA-approved. This is not an endorsed protocol. Physician review required before use.
PeptideReport.ai
Recovery Guides › Wolverine Stack

Research Guide · Tissue Repair & Recovery

The Wolverine Stack

BPC-157 + TB-500 · the most-discussed recovery pairing in peptides

Two repair peptides that heal in opposite directions — one local, one systemic — combined into the single most searched recovery protocol in the space. The reason it's paired isn't hype: the two compounds attack tissue repair and blood-vessel growth from complementary angles. Here's the mechanism, the protocol, and the one caution that actually matters.

Local + Systemic RepairVEGF SynergySame-Syringe CompatibleInjury & RecoveryResearch Compounds
LocalBPC-157
SystemicTB-500
VEGF ×2Signal + receptors
4–8 wkTypical course

Why This Guide Exists

The famous stack, explained without the fan fiction

"Wolverine Stack" is a nickname, and the nickname does a lot of damage — it promises comic-book healing and skips the biology. The truth is more useful: this pairing is popular because the two peptides genuinely complement each other, and it carries a specific risk that the hype never mentions. This guide gives you both — why it works, how it's run, and who should never touch it.

In one sentenceBPC-157 heals locally and raises the VEGF receptors; TB-500 heals systemically and raises VEGF production — so the stack drives tissue repair and new blood-vessel growth from both the signal side and the sensor side at once.

The Two Compounds

Same goal, opposite reach

Local / Targeted

BPC-157

  • Gastric pentadecapeptide (15 aa)
  • Works at the injury site — tendon, ligament, gut
  • Increases VEGF receptors (VEGFR2)
  • Best for localized tendon/ligament and gut repair
  • Daily dosing; flexible timing
+
Systemic / Body-Wide

TB-500

  • Thymosin β4 fragment
  • Works throughout the body — mobilizes repair cells
  • Increases VEGF production (the signal itself)
  • Best for muscle and whole-body recovery
  • Longer half-life; less frequent dosing

Why they're considered synergistic

Angiogenesis — growing new blood vessels into damaged tissue — needs both a signal and the sensors to receive it. TB-500 raises the signal; BPC-157 raises the sensors. Neither maximizes the pathway alone; together they hit it from both ends.

TB-500 → ↑ VEGF (signal) · BPC-157 → ↑ VEGFR2 (receptors) → amplified angiogenesis & repair

Mechanism

How the stack heals

01

Blood supply to damaged tissue

Both compounds drive angiogenesis — more blood vessels means more oxygen, nutrients, and repair cells reaching the injury. This is the shared engine of the stack, and the source of both its benefit and its cancer caution.

02

Cell migration and tissue reorganization

TB-500 sequesters actin to mobilize repair and stem cells toward damage; BPC-157 activates repair pathways locally. The result is coordinated rebuilding rather than a single-point patch.

03

Anti-inflammatory action

Both reduce local and systemic inflammation, which is often what stalls healing — turning a chronically inflamed, non-healing injury back toward an active repair state.

04

Different tissues, covered together

BPC-157 shines on tendon, ligament, and gut; TB-500 on muscle and body-wide soft tissue. The combination covers the tissue types a single compound would leave out.

Protocol

How the stack is run

Educational reference from the platform's locked library — not prescribing guidance. Both are investigational; use warrants physician oversight and a verified source.

BPC-157≈ 250–500 mcg daily

Daily subcutaneous, flexible timing (AM/PM or bedtime), no fasting required. Often dosed near the injury for localized issues.

TB-500≈ 250–500 mcg, consistent schedule

Longer half-life allows less-frequent dosing than BPC-157; PM or rest-day timing is common, no fasting required. (Higher community "loading" protocols exist but sit outside this educational reference range.)

Course length4–8 weeks on, then reassess

Acute injuries: ~4–6 weeks. Both support an active repair process — progressive loading or physical therapy during the course determines how durable the result is. Stopping before ~4 weeks rarely gives lasting benefit.

The syringe detail people get wrongFor immediate use, BPC-157 and TB-500 can be drawn into the same syringe — a genuine convenience unique to this pairing. Understand your response to each compound individually before combining them.

Timeline

What to expect

The Caution That Matters

Angiogenesis cuts both ways

Cancer history — do not useThe stack heals by growing new blood vessels. Tumors also depend on new blood vessels for their supply. In someone with existing or prior cancer, that same mechanism is a theoretical risk. The consistent consensus across clinicians and the research community: anyone with a history of cancer, active cancer, or known predisposition should not use BPC-157 or TB-500.

Common Questions

Wolverine Stack questions answered

Why combine them instead of using one?
Because they cover different ground. BPC-157 is local and best for tendon, ligament, and gut; TB-500 is systemic and best for muscle and whole-body recovery. On the blood-vessel-growth pathway they're complementary — TB-500 raises the VEGF signal, BPC-157 raises its receptors — so together they drive repair more completely than either alone.
Can I really put both in one syringe?
Yes — for immediate use, drawing BPC-157 and TB-500 into the same syringe is standard practice for this stack. That's unusual; many peptides must stay separate. It's part of why the pairing is so popular.
Who absolutely should not use it?
Anyone with a personal history of cancer, active cancer, or elevated cancer risk — the angiogenesis mechanism is a theoretical tumor risk. Also tested athletes (WADA-banned), and caution with traumatic brain injury history. Pregnancy and breastfeeding: avoid.
How long until it works, and does it last?
Pain usually eases in the first 1–2 weeks; functional recovery builds over 4–8 weeks. Durability depends on doing the rehab — progressive loading or physical therapy — during the cycle. These support an active repair process; they don't passively fix tissue while you rest.

About the Author

SD
Dr. Scott DelBoccio, DMD
Founding Author · PeptideReport.ai

Dr. DelBoccio is a clinician with thirty years of practice and a focus on peptide pharmacology and regenerative medicine. PeptideReport.ai is the clinician-authored, education-only reference the peptide space lacked — every guide is an independent synthesis of the primary literature, evidence-graded and corrected in the open. No products are sold on this site.

Full Disclaimer

BPC-157 and TB-500 are not approved by the U.S. Food and Drug Administration for any indication and are research compounds; the "Wolverine Stack" is a community protocol, not a medically endorsed therapy. Information on this page is for educational and scientific purposes only and does not constitute medical advice, diagnosis, or treatment. Both compounds carry a theoretical angiogenesis-related cancer caution and lack long-term human safety data. Any use should be under the supervision of a qualified physician, and individuals with any cancer history should not use these compounds. PeptideReport.ai does not manufacture, sell, or endorse any preparation. Content addresses adults 21 and older. Evidence and regulatory classifications continue to evolve.